NCT02508506View on ClinicalTrials.gov

Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function

PHASE1CompletedINTERVENTIONAL

Enrollment

22

Participants

Timeline

Start Date

July 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

Renal Impairment

Interventions

DRUG

ALKS 5461

Single dose, given orally

Trial Locations (3)

32809

Alkermes Investigational SIte, Orlando

55404

Alkermes Investigational Site, Minneapolis

80228

Alkermes Investigational SIte, Denver

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Alkermes, Inc.

INDUSTRY